Surveillance of Antifungal Resistance in Candidemia Fails to Inform Antifungal Stewardship in European Countries
- PMID: 35330251
- PMCID: PMC8950249
- DOI: 10.3390/jof8030249
Surveillance of Antifungal Resistance in Candidemia Fails to Inform Antifungal Stewardship in European Countries
Abstract
Background: The increasing burden of candidemia and the emergence of resistance, especially among non-Candida albicans strains, represent a new threat for public health. We aimed to assess the status of surveillance and to identify publicly accessible resistance data in Candida spp. blood isolates from surveillance systems and epidemiological studies in 28 European and 4 European Free Trade Association member states.
Methods: A systematic review of national and international surveillance networks, from 2015 to 2020, and peer-reviewed epidemiological surveillance studies, from 2005 to 2020, lasting for at least 12 consecutive months and with at least two centers involved, was completed to assess reporting of resistance to amphotericin B, azoles, and echinocandins in C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, C. krusei, and C. auris.
Results: Only 5 (Austria, Italy, Norway, Spain, and United Kingdom) of 32 countries provided resistance data for Candida spp blood isolates. Among 322 surveillance studies identified, 19 were included from Belgium, Denmark, Iceland, Italy, Portugal, Spain, Sweden, Switzerland, and United Kingdom. C. albicans and C. glabrata were the most monitored species, followed by C. parapsilosis and C. tropicalis. C. krusei was not included in any national surveillance system; 13 studies assessed resistance. No surveillance system or study reported resistance for C. auris. Fluconazole, voriconazole, caspofungin, and amphotericin B resistance in C. albicans, C. glabrata, and C. parapsilosis were the most common drug-species combination monitored. Quality of surveillance data was poor, with only two surveillance systems reporting microbiological methods and clinical data. High heterogeneity was observed in modalities of reporting, data collection, and definitions.
Conclusion: Surveillance of antifungal resistance in Candida spp blood-isolates is fragmented and heterogeneous, delaying the application of a translational approach to the threat of antifungal resistance and the identification of proper targets for antifungal stewardship activities. International efforts are needed to implement antifungal resistance surveillance programs in order to adequately monitor antifungal resistance.
Keywords: candidemia; resistance; stewardship; surveillance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Similar articles
-
Candida and candidaemia. Susceptibility and epidemiology.Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
-
Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance.J Antimicrob Chemother. 2015 Mar;70(3):802-10. doi: 10.1093/jac/dku460. Epub 2014 Dec 3. J Antimicrob Chemother. 2015. PMID: 25473027
-
Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.Clin Microbiol Infect. 2014 Jul;20(7):698-705. doi: 10.1111/1469-0691.12440. Epub 2013 Dec 12. Clin Microbiol Infect. 2014. PMID: 24188136
-
Candida tropicalis is the most prevalent yeast species causing candidemia in Algeria: the urgent need for antifungal stewardship and infection control measures.Antimicrob Resist Infect Control. 2020 Apr 7;9(1):50. doi: 10.1186/s13756-020-00710-z. Antimicrob Resist Infect Control. 2020. PMID: 32264966 Free PMC article.
-
Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.J Hosp Infect. 2002 Apr;50(4):243-60. doi: 10.1053/jhin.2001.1151. J Hosp Infect. 2002. PMID: 12014897 Review.
Cited by
-
Susceptibility patterns of Candida species collected from intensive care units in Portugal: a prospective study in 2020-2022.Infect Prev Pract. 2024 Sep 24;6(4):100403. doi: 10.1016/j.infpip.2024.100403. eCollection 2024 Dec. Infect Prev Pract. 2024. PMID: 39886460 Free PMC article.
-
Diagnosis and Treatment of Invasive Candidiasis.Antibiotics (Basel). 2022 May 26;11(6):718. doi: 10.3390/antibiotics11060718. Antibiotics (Basel). 2022. PMID: 35740125 Free PMC article. Review.
-
Antifungal Activity of Mexican Propolis on Clinical Isolates of Candida Species.Molecules. 2022 Sep 1;27(17):5651. doi: 10.3390/molecules27175651. Molecules. 2022. PMID: 36080417 Free PMC article.
-
Multicentre Surveillance of Candida Species from Blood Cultures during the SARS-CoV-2 Pandemic in Southern Europe (CANCoVEU Project).Microorganisms. 2023 Feb 23;11(3):560. doi: 10.3390/microorganisms11030560. Microorganisms. 2023. PMID: 36985134 Free PMC article.
-
The Impact of the Fungal Priority Pathogens List on Medical Mycology: A Northern European Perspective.Open Forum Infect Dis. 2024 Jul 1;11(7):ofae372. doi: 10.1093/ofid/ofae372. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39045012 Free PMC article. Review.
References
-
- Fournier P., Schwebel C., Maubon D., Vesin A., Lebeau B., Foroni L., Hamidfar-Roy R., Cornet M., Timsit J.F., Pelloux H. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. J. Antimicrob. Chemother. 2011;66:2880–2886. doi: 10.1093/jac/dkr394. - DOI - PubMed
-
- Shah D.N., Yau R., Lasco T.M., Weston J., Salazar M., Palmer H.R., Garey K.W. Impact of prior inappropriate fluconazole dosing on isolation of fluconazole-nonsusceptible Candida species in hospitalized patients with candidemia. Antimicrob. Agents Chemother. 2012;56:3239–3243. doi: 10.1128/AAC.00019-12. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous